Argenx announced on October 19, 2026, the forthcoming presentation of results from the phase 3 ALKIVIA study in autoimmune myositis, whose primary endpoint was met with a difference of 15.4 points in favor of efgartigimod on the Total Improvement Score (TIS) at 52 weeks. This result applies to the combined population of patients with immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM). According to the group, therapeutic options are limited in these two forms, and there is no approved treatment in IMNM.<br><br>This publication comes shortly after the discontinuation, announced on October 8, 2026, of the phase 3 UNITY trial of the same molecule in Sjögren's disease, on the recommendation of an independent data monitoring committee which determined that the study would not be able to achieve its primary endpoint. ALKIVIA, presented by Argenx as the first registration study of an FcRn blocker in autoimmune myositis, will be detailed on November 11, 2026 at the ACR Conv…

Encuentre las cotizaciones de acciones, el historial, las noticias y otra información vital más reciente de argenx SE (ARGX) para ayudarle con su negociación e inversión en acciones.

Results from the global Phase 3 ALKIVIA study, the first registrational study investigating an FcRn blocker in autoimmune myositis, show efgartigimod provides clinically...

Results from the global Phase 3 ALKIVIA study, the first registrational study investigating an FcRn blocker in autoimmune myositis, show efgartigimod provides clinically meaningful improvements in IMNM and DMPatient improvements observed as early as Week 4 and sustained through 52 weeksLate-breaking oral presentation on Wednesday, November 11th, 9:15 – 9:30 AM ET October 19, 2026, 8:00 AM ET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), the immunology innovation company, toda

Shares of Forte Biosciences (FBRX) surged nearly 40% in premarket trading Monday after Argenx (ARGX) agreed to acquire the clinical-stage biotech company in an all-cash deal valued at approximately $2.2 billion, giving the immunology specialist a promisin

View the basic ARGX option chain and compare options of argenx SE on Yahoo Finance.

For those with celiac disease, even a little bit of gluten can cause damage to the intestine.

View argenx SE Sponsored ADR ARGX stock quote prices, financial information, real-time forecasts, and company news from CNN.